Quarterly Result24 Jul 2026, 09:20 pm
Onesource Pharma Q1FY27 Revenue up 37% to ₹4,490m
AI Summary
OneSource Specialty Pharma Ltd announced strong Q1FY27 results with revenue surging 37% year-on-year to ₹4,490 million and EBITDA growing 39% year-on-year to ₹1,233 million. This robust performance was driven by the commercial launch of semaglutide in Canada and India, new MSA contracts, and customer wins. EBITDA margins expanded to 27.5%. The company reaffirmed its FY28 guidance of $400 million in organic revenue with a 40% EBITDA margin. The CEO highlighted the upcoming commercial operations of a second cartridge line in Q2 and the addition of a new global biosimilar customer, underscoring the company's integrated CDMO capabilities and capacity expansion.
Key Highlights
- Revenue increased 37% YoY to ₹4,490m, driven by semaglutide launch and new contracts.
- EBITDA grew 39% YoY to ₹1,233m, with margins expanding to 27.5%.
- Adjusted PAT rose 72% YoY to ₹637m, with Adjusted EPS at ₹5.6.
- FY28 guidance reaffirmed at $400m organic revenue and 40% EBITDA margin.
- Second cartridge line to commence commercial operations in Q2 FY27.
Price Impact
More from ONESOURCE